ICER posts draft scoping document for beta-thalassaemia treatment, betibeglogene autotemcel.
In: PharmacoEconomics & Outcomes News, Jg. 893 (2021-12-11), Heft 1, S. 35-35
serialPeriodical
Zugriff:
Current treatment involves lifelong blood transfusions or haematopoietic stem cell therapy, which is most effective in patients under 14 years of age with a matching HLA donor. The Institute for Clinical and Economic Review (ICER) has issued a draft scoping document outlining its planned review of the comparative clinical effectiveness and economic value of betibeglogene autotemcel [Zynteglo/LentiGlobin; bluebird bio] for the treatment of beta-thalassaemia. [Extracted from the article]
Titel: |
ICER posts draft scoping document for beta-thalassaemia treatment, betibeglogene autotemcel.
|
---|---|
Zeitschrift: | PharmacoEconomics & Outcomes News, Jg. 893 (2021-12-11), Heft 1, S. 35-35 |
Veröffentlichung: | 2021 |
Medientyp: | serialPeriodical |
ISSN: | 1173-5503 (print) |
DOI: | 10.1007/s40274-021-08266-7 |
Schlagwort: |
|
Sonstiges: |
|